灵芝孢子对原发性肝癌术后复发影响的研究

Inhibitory efficacy of ganoderma lucidium spore on recurrence after curative resection of hepatocellular carcinoma

目的探究灵芝孢子预防原发性肝癌根治术后复发的作用。方法采用完全随机对照的前瞻性临床研究,60例行根治切除的原发性肝癌患者随机分为术后常规治疗组和灵芝孢子治疗组,随访2年,观察术后无瘤生存率(DFS)、总体生存率(OS)和灵芝孢子的安全性。结果两组患者年龄、性别构成比、肿瘤大小以及术前AFP>20ng/ml、微血管侵犯、肿瘤卫星结节、乙肝感染、肝硬化患者比例的差异无统计学意义;术后抗病毒治疗患者比例以及术中输血、住院时间比较,差异无统计学意义(P<0.05)。术后常规治疗组和灵芝孢子治疗组的2年无瘤生存率分别为53.3%和70.0%(P=0.034),2年总生存率分别为60.0%和83.3%(P=0.023),差异有统计学意义。术后两组患者的并发症和药物副反应发生率无显著性差异(P=0.371)。结论灵芝孢子可以减少肝癌根治术后复发,安全有效。

Objective To evaluate the clinical efficacy of ganoderma lucidium spore (GLS) on recurrence after curative resection of hepatocellular carcinoma (HCC). Methods Sixty patients undergoing curative resection of HCC were randomly divided into conventional treatment group and GLS treatment group. After two years of follow-up , the disease-free survival (DFS) and overall survival (OS) were compared between the two groups. Results There were no significant differences in age , gender, tumor size, intraoperative blood loss, hospital stay, the proportions of the patients with AFP more than 20 ng / ml , microvascular invasion , tumor satellite nodules , Hepatitis B virus infection, cirrhosis and postoperative anti-virus therapy, between the two groups (P<0.05). The 2-year DFS were 53.3% and 70.0% (P=0.034), 2-year OS were 60.0% and 83.3% (P=0.023), respectively in the conventional treatment group and GLS group. There were no significant differences in postoperative complication rate between the two groups (P=0.472), and only one case developed diarrhea due to adverse effect of GLS. Conclusion GLS treatment is safe and effective to inhibit tumor recurrence and improve DFS and OS of the patients after radical resection for HCC.